Introduction: Malnutrition is common in end-stage renal disease (ESRD) and affects both morbidity and mortality. The growth hormone-dependent insulin-like growth factor (IGF)-I may be a good marker of malnutrition because of its short half-life. In the present study, we investigate the influence of decreasing residual renal function as well as of chronic inflammation on the IGF system to assess its usefulness in this patient group. Patients and methods: Cross-sectional analysis of 220 ESRD patients (140 males) with a mean age of 5271 years. Biochemical analyses of insulin, IGF-I, IGFBP-1, IGFBP-3, IL-6, high sensitivity (hs)-CRP and other routine markers. Malnutrition status was recorded using subjective global assessment (SGA), body mass index, estimated protein intake from nitrogen appearance (nPNA), handgrip strength (HGS) and insulin resistance (HOMA-IR). Dual energy X-ray absorptiometry was used to assess body composition. Results: Both IGF-I and IGFBP-1 showed significant and opposite correlations with most markers of nutritional status, including SGA (r ¼ À0.29 and 0.27; Po0.001), nPNA (r ¼ 0.18 and À0.22; Po0.05), S-creatinine (r ¼ 0.19 and À0.19; Po0.01) and HGS (r ¼ 0.21 and À0.25; Po0.01). IFG-I was strongly correlated with IGFBP-3 (r ¼ 0.62; Po0.001) and inversely correlated with IGFBP-1 (r ¼ 0.44; Po0.001). Both IGF-I and IGFBP-3, but not IGFBP-1, were significantly correlated with age (r ¼ À0.25 for IGF-I and À0.35 for IGFBP-3; Po0.001) and hsCRP (r ¼ À0.21 and À0.32; Po0.01). In multivariate analysis, SGA and s-albumin were independent predictors of both IGF-I and IGFBP-1. Conclusion: Both IGF-I and IGFBP-1 appear to correlate well with markers of protein-energy malnutrition and sarcopenia. However, IGF-I is also influenced by age, whereas IGFBP-1 is influenced by glucose metabolism. IGFBP-3 does not correlate with nutritional status in ESRD, perhaps because of a strong association with inflammation.
Introduction
Protein-energy malnutrition (defined here as too low intake of nutrients) and sarcopenia (defined here as muscle catabolism) are common phenomena in end-stage renal disease (ESRD) and affect both patient morbidity and mortality (Bergstrom, 1995) . Insulin-like growth factor (IGF)-I is a circulating plasma protein involved in fetal and adult growth (Powell et al., 1998; Owino et al., 2001 ) that shares a large degree of structural homology to insulin, including an ability to bind to insulin receptors (De Meyts and Whittaker, 2002) . In adult ESRD patients, reduced IGF-I activity has been postulated to be an important mediator of growth hormone (GH) resistance (Powell et al., 1996) influenced by residual renal function, likely because of a decreased clearance of binding proteins that have a predominantly inhibitory effect on IGF-I signaling (Powell et al., 1996) . Furthermore, several studies have shown a link between inflammation and IGF-I activity (Lazarus et al., 1993; de Martino et al., 2000) , which is decreased in inflamed individuals. The activity of IGF-I is also determined by its many binding proteins, the two most prominent being IGFBP-1 and IGFBP-3 (Brismar et al., 1994; Iglesias et al., 2004) . Whereas IGFBP-3 is thought to be the main carrier protein of IGF-I in plasma (Brismar et al., 1994) , IGFBP-1 may participate in autocrine or paracrine regulation of IGF bioavailability locally in the target tissue.
Although malnutrition and sarcopenia are common phenomena in ESRD, we currently lack simple and clinically acceptable tools to assess nutritional status in renal patients. IGF-I levels may be a good marker of malnutrition and/or sarcopenia in ESRD and have been used as such in other patient groups (Justova et al., 2001; Ranke et al., 2001) . In the present study, we thus investigate the influence of decreasing residual renal function as well as of the chronic inflammation often present in ESRD on the IGF-system to assess its usefulness as a nutritional marker in renal patients.
Material and methods
Patients Two hundred and twenty ESRD patients (140 males; 64%) with a mean age of 5271 years were studied in a crosssectional analysis shortly before start of RRT (mean glomerular filtration rate 6.470.2 ml/min). All the patients were incident ESRD patients enrolled in the dialysis program at the Karolinska University Hospital at Huddinge between 1997 and . They are all included as participants in an ongoing prospective study, parts of which were previously described (Stenvinkel et al., 1999; Axelsson et al., 2004) . The study exclusion criteria were age below 18 years or above 70 years, clinical signs of acute infection, acute vasculitis or liver disease at the time of evaluation, or unwillingness to participate in the study. The causes of ESRD were chronic glomerulonephritis in 60 patients, diabetic nephropathy in 62 patients, polycystic kidney disease in 24 patients and other or unknown etiologies in 74 patients. Forty-four (20%) patients were diagnosed with type I diabetes mellitus (DM), defined as insulin dependent from the onset of the disease, whereas 26 (12%) were diagnosed with type II DM, defined as initially non-insulin-dependent. In accordance with current therapy recommendations, most (n ¼ 24) of the patients initially taking oral antiglycemic agents or on restricted diets had been switched to insulin therapy at the time of inclusion in the study.
Seventy-five of the patients (34%) had clinical CVD as defined by medical history and/or clinical findings of one or more of cerebrovascular disease, cardiovascular disease and peripheral ischemic disease at the time of enrollment. Thirty-eight (17%) patients had had one or more myocardial infarctions and/or clinical signs of ischemic heart disease (angina pectoris). Most patients were on antihypertensive medications (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor antagonists, n ¼ 108, betablockers, n ¼ 119; calcium-channel blockers, n ¼ 132) and other commonly used drugs in terminal ESRD, such as phosphate and potassium binders, diuretics, iron substitution and vitamin B, C and D supplementation. Eighty of the patients were on lipid-lowering medication (HMG-CoAreductase inhibitors). The Ethics Committee of the Karolinska Institute approved the study at the Karolinska University Hospital, Huddinge, and informed consent was obtained from each patient.
Methods
After an overnight fast, venous blood samples were drawn and stored at À701C for biochemical analyses. The glomerular filtration rate, as estimated by the mean of creatinine and urea clearance, was calculated from 24-h urinary samples collected from 200 patients. Plasma analysis for free insulin, IGF-I, IGFBP-1 and IGFBP-3 were performed on an IMMULITE s system (DPC Corp., Los Angeles, CA, USA) using commercially available assays (from DPC Corp. PILKIN-10, PILKGF-7 and PILKGB-3 for insulin, IGF-I, and IGFBP-1 respectively, and for IGFBP-1 MX52021 from IBL GmbH, Hamburg, Germany). Plasma IL-6 was also analyzed by ELISA using a commercially available kit (Roche Diagnostics GmbH, Penzberg, Germany). The levels of serum cholesterol and triacylglycerols were analyzed by standard enzymatic procedures (Roche Diagnostics GmbH). High sensitivity (hs)-CRP (n ¼ 157) was analyzed using an immunonephelometric procedure (Behring AG, Marburg, Germany), whereas the remaining biochemical analyses were performed using routine methods at the Department of Clinical Chemistry at Karolinska University Hospital at Huddinge.
Nutritional status was assessed by subjective global assessment (SGA: n ¼ 215) (Detsky et al., 1987; Qureshi et al., 1998) recorded at the time of inclusion, concurrent with the drawing of blood samples. Body mass index (BMI) was calculated as weight (kg)/(height (m)) 2 . Estimated protein intake (normalized protein equivalent of nitrogen appearance: nPNA) was calculated by the formula 6.25((0.028 Â urea excretion rate) þ (0.031 Â body weight))/ standard body weight according to age, height and gender (n ¼ 180) as reported in the NHANES III study (Statistics NCfH, 1996) , whereas energy intake was not assessed. Insulin resistance was calculated by the homeostasis model assessment (HOMA-IR): fasting plasma insulin (mU/ ml) Â fasting plasma glucose (mmol/l)/22.5. Handgrip strength (HGS) was evaluated in both the dominant and non-dominant arms using the Harpenden Handgrip Dynamometer (Yamar, Jackson, MI, USA). HGS was repeated three times and the highest value was noted. Lean body mass (LBM) and truncal fat mass (FM) were estimated by dual energy X-ray absorptiometry (DXA) using the DPX-L device (Lunar Corp., Madison, WI, USA). With this technique, fat and LBM distribution are directly estimated without making assumptions about the two-compartment model. DXA has proved to be superior to other simple non-invasive methods for determining body composition in renal failure, especially if repeated measurements are made (Kerr et al., 1996) . However, it must be kept in mind that, although the state of hydration does not affect the estimate of FM with DXA, it does affect that of LBM.
Statistical analysis
Results are expressed as mean and standard error, unless otherwise indicated, with Po0.05 indicating significance. Comparisons between groups were made using nonparametric ANOVA. If significant differences were found, further analysis was made using Dunnet's test. As many values were not normally distributed, correlations between markers were calculated by Spearman's rank. For measuring influence of more than one parameter on the studied variables, three-way multivariate analysis of variance with Wilk's lambda was used. The model included a test for the effect of order. The general linear model procedure with least square means was used to identify significant interactions between factors. When significant interactions were found between factors (A Â B) these were identified with the simple main effects tests. Stepwise multivariate regression analysis was used to assess the predictors for plasma levels of IGF-I and its binding proteins 1 and 3. Cook's distances were used to identify patients with a disproportional impact on the regression model and, as these were found to be present in all patients with dependent variable values 43 s.d. from the mean, these patients were excluded from the model (no10 in each model). All analyses were performed using the statistical software SAS s version 8.2 (SAS Inc., Campus Drive, Cary, NC, USA).
Results

Baseline data
Baseline clinical, nutritional and biomarkers of the patients, divided into eight groups according to gender, nutritional status (SGA 1 or 2-3) and inflammation (CRP o10 or X10 mg/l), are summarized in Table 1 . In this table, the significant differences and interactions between the groups are also indicated in the rightmost column. Interestingly, while HGS, LBM, BMI and serum albumin are significantly influenced by gender, malnutrition and in some cases inflammation, IGF-I and IGFBP-1 are only influenced by nutritional status.
Impact of diabetes mellitus
Basal characteristics divided according to the presence and type of diabetes mellitus are given in Table 2 . As expected, type II DM was observed in older patients (59.771.5 years) compared to both type I DM (49.071.9 years; P ¼ 0.001) and non-DM patients (51.671.0 years; P ¼ 0.001). The prevalence of CVD was also significantly higher in the type II DM (77%) than in either type I DM (39%; Po0.001) or in non-DM (25%; Po0.001). The prevalence of protein-energy malnutrition (SGA) tended to be lower among non-diabetic patients, although this difference was not statistically significant (P ¼ 0.05). Diabetic patients also had a significantly decreased HGS (25.371.7 kg for type I and 28.072.0 kg for type II DM, as compared to 33.371.0 kg for non-DM; Po0.001) and serum creatinine (7.470.3 and 7.270.6 mg/dl vs 8.670.2 mg/dl; Po0.001). No significant differences in estimated protein intake (by nPNA) or LBM (by DEXA) were observed between the three groups.
When compared to non-diabetic patients, both type I and II DM patients had significantly lower levels of serum IGF-1 (167.4714.2 ng/ml in type I DM and 146.2714.1 ng/ml in type II DM vs 191.678.0 ng/ml in non-DM; Po0.05) and serum IGFBP-3 (4.770.2 and 4.270.3 mg/ml vs 5.470.1 mg/ ml; Po0.001). On the other hand, serum levels of IGFBP-1 were elevated in DM as compared to non-DM (31.874.4 mg/l in type I and 17.773.7 mg/l in type II vs 15.370.9 mg/l in non-diabetic patients; Po0.001). Compared to expected values in healthy individuals according to age as reported by the manufacturer, both IGF-1 and IGFBP-3 values were within 1s.d. of expected values for all three groups, whereas levels of IGFBP-1 were elevated threefold in type II and non diabetic patients, and almost sevenfold in type I DM patients (data not shown).
Nutritional status in relation to IGF, IGFBP-1 and IGFBP-3
The associations between IGF and its binding proteins 1 and 3, with surrogate markers of nutritional status, are given in Table 3 . IGF-I was strongly correlated with IGFBP-3 (r ¼ 0.62, Po0.001) and inversely correlated with IGFBP-1 (r ¼ 0.44, Po0.001) as shown in Figure 1 . In univariate analysis, both IGF-I and IGFBP-1 showed significant and opposite correlations with most markers of nutritional status, including SGA (r ¼ À0.29 and 0.27; Po0.001), nPNA (r ¼ 0.18 and À0.22; Po0.05), S-creatinine (r ¼ 0.19 and À0.19; Po0.01), HGS (r ¼ 0.21 and À0.25; Po0.01), Salbumin (r ¼ 0.36 and À0.23; Po0.01) and BMI (r ¼ 0.14 and À0.39; Po0.05). Only IGFBP-1 was associated with LBM (r ¼ À0.25; Po0.001). Both IGF-I and IGFBP-3, but not IGFBP-1, were significantly correlated with age (r ¼ À0.25 for IGF-I and À0.35 for IGFBP-3; Po0.001) and hsCRP (r ¼ À0.21 and À0.32; Po0.01), whereas all three biomarkers were significantly associated with the presence of DM (r ¼ À0.17 for IGF-I, 0.16 for IGFBP-1 and À0.27 for IGFBP-3; Po0.05). There was no correlation between GFR and IGF-I, IGFBP-1 or IGFBP-3.
Glucose metabolism in relation to IGF-I, IGFBP-1 and IGFBP-3 Important relationships between markers of glucose metabolism and IGF-I, IGFBP-1 and IGFBP-3 can be found in 
Significant (Po0.05) differences between groups are indicated for gender (A), malnutrition (B) and inflammation (C), as well as any significant interactions. Normal ranges in healthy adults (median and range as reported by the manufacturer of the kits) are for IGF-I 144 (87-238) ng/ml, for IGFBP-1 4.4 (0.6-14.4) mg/l and for IGFBP-3 4.8 (3.4-6.9) mg/l. 
Inflammation in relation to IGF-I, IGFBP-1 and IGFBP-3
Elevated serum levels of hsCRP were associated with lower levels of both IGF-I and IGFBP-3 (r ¼ À0.21 and À0.32; Po0.01), but had no significant impact on levels of IGFBP-1 (Table 3) . Whereas a significant correlation between concentrations of IGFBP-3 and IL-6 (r ¼ À0.40; Po0.001) was present, no correlation was observed between serum levels of IL-6 and either IGF-I or IGFBP-1.
Independent predictors of IGF-I, IGFBP-1 and IGFBP-3
To evaluate the relative importance and independence of the observed correlations, we performed a multiple regression analysis separately for each of the three main variables, adding all factors that had been found to be associated with the investigated variable in univariate analysis as well as age and gender. The resulting models are shown in Table 4a 
Discussion
Because synthesis of IGF-I in vivo is primarily determined by body size (Gourmelen et al., 1984) , GH (Hardouin et al., 1989) and nutritional intake (Lee and Rosenfeld, 1987) , and as it has a relatively short plasma half-life of 4-6 h (Hintz, 1984) , it has been suggested as a marker of nutrition in other patient groups, including children with GH-deficiency (Ranke et al., 2001 ) and patients receiving parenteral nutrition (Justova et al., 2001) . IGF-I has previously also been measured in several studies on ESRD patients (Jacob Qureshi et al., 1998) . However, to our knowledge no one has previously systematically looked at the correlation of circulating IGF-I, IGFBP-1 and IGFBP-3 with multiple markers of nutritional status in this patient group. Both IGF-I and IGFBP-1 correlated well with the studied markers of protein-energy malnutrition and sarcopenia (Table 3) . Indeed, IGF-I is thought to induce target cell amino-acid uptake and protein de novo synthesis, which is reflected by an improvement in nitrogen balance in calorically restricted volunteers (Clemmons et al., 1995) . Although IGF-I is likely to have an impact on muscle mass and function (Borst and Lowenthal, 1997; Musaro et al., 2001) , conflicting results regarding the functional consequences of this have been reported in the literature (Papadakis et al., 1995; Boonen et al., 1998; Janssen et al., 1998; Kostka et al., 2000; Cappola et al., 2001; Owino et al., 2001 ). In a cross-sectional study of 245 healthy elderly women (Boonen et al., 1998) , plasma IGF-I levels could not explain the age-associated decline of muscle function. Also, Papadakis et al. (1995) found that an initially observed significant association of plasma IGF-I with HGS and knee muscle strength was lost after adjusting for age. On the other hand, a recent epidemiological study by Owino et al. (2001) . in older women showed that low plasma IGF-I levels were associated with poor knee extensor muscle strength and slow walking speed independently of IL-6. Moreover, in vitro muscle tissue from elderly people stimulated with mechanical overload show less activation of satellite cells and develop less hypertrophy if they express less autocrine IGF-I and/or have an inability to upregulate the IGF-I receptor (Owino et al., 2001) . Taken together, although some findings suggest a role for IGF-I in the causal pathway leading to sarcopenia in the elderly (Cappola et al., 2001) , further studies are clearly needed to clarify the pathways involved and their relative importance in ESRD. The amount of free IGF-I able to act upon the target receptors is also very much dependent on at least six different IGF-binding proteins, the two most prominent in the systemic circulation being IGFBP-1 and IGFBP-3 (Tonshoff et al., 1995; Frystyk et al., 1999) , levels of which are altered in renal failure (Ding et al., 1997; Iglesias et al., 2004) . Whereas the main source of circulating IGF-I and IGFBP-1 is considered to be the liver (Brismar et al., 1994) , the main source(s) of circulating IGFBP-3 is not known. IGF-I and IGFBP-3 are GH dependent (Ranke et al., 2001) , whereas IGFBP-1 is mainly regulated by insulin (Brismar et al., 1994) . In the present study, free serum IGF-I was associated with serum levels of IGFBP-3 and inversely correlated with IGFBP-1 (Figure 1) . However, whereas IGF-I and IGFBP-3 were found to be within the normal range, levels of IGFBP-1 were increased almost threefold in type II diabetic and non-diabetic patients, and almost sevenfold in type I diabetic patients, as compared to the normal levels reported by the kit manufacturer. This is in agreement with previous studies in ESRD (Tonshoff et al., 1995; Frystyk et al., 1999; Iglesias et al., 2004) . Thus, while IGF-I does not appear to correlate well with GFR (Iglesias et al., 2004) , ESRD may instead result in disturbances of both synthesis and bioavailability of IGF-I through effects on its binding proteins, as well as through the generally elevated levels of GH (Tonshoff et al., 1995; Divino Filho et al., 1998) seen in these patients.
Given the observed differences in IGFBP-1 levels between diabetic and non-diabetic patients in the present study (Table 2) , the published reports regarding IGFBP-1 regulation by insulin (Brismar et al., 1994) , as well as its strong association to markers of glucose metabolism (Table 3 and Figure 2 ), it could be speculated that insulin and glucose metabolism are important modulators of the IGF-system also in ESRD. In diabetics patients without renal disease, insulin is thought to be an important determinant of IGFBP-1 production and thus of IGF-I bioavailability (Kaufman and Catanese, 1995) , and our observation of a strong correlation between insulin, glucose and IGFBP-1 agree with those reported previously in children with ESRD (Tonshoff et al., 1995) and in HD patients . Indeed, IGFBP-1 production in the liver is known to be strongly influenced by carbohydrate intake (Wolk et al., 2004) , and administration of recombinant IGFBP-1 leads to increased secretion of insulin in rats (Mortensen et al., 1997) , whereas IGF-I is known to counteract GH-induced suppression of insulin synthesis (Moses et al., 1996) . This may explain the very strong and independent associations between IGFBP-1 and the markers of glucose metabolism found in the present study.
Although we demonstrated an association between serum hsCRP and IGF-I levels, no significant association between Figure 2 The linear relationship between serum IGF-BP1 and fasting P-glucose in 140 male (K) and 80 female (J) ESRD patients just before the start of RRT. The initial model included changes in IGF-BP1 as the dependent parameter, and age, gender, S-albumin, inflammation (S-CRPX10 mg/l), diabetes mellitus, subjective global assessment (SGA), serum creatinine and hand grip strength as independent parameters. IGF-I and IL-6 was found in the present study. In previous studies, IL-6 has been postulated to inhibit the secretion of IGF-I (Lazarus et al., 1993; de Martino et al., 2000) . However, a recent study by Barbieri et al. (2003) . in healthy individuals of all ages provided evidence for a more complex relationship between inflammation and IGF-I. The results of this study suggest that high IL-6 levels may act on IGF-I receptors (Shen et al., 2002) as well as on IGF-I and its binding proteins (Gibson and Cohen, 1999) , downregulating them to such low levels that the effect of IGF-I on muscle is lost, while the full effect of low IGF-I on muscle is apparent only when IL-6 plasma levels are also low (Barbieri et al., 2003) . Indeed, in the present study, IL-6 is negatively associated with serum IGFBP-3, as is advanced age and DM, two conditions known to be associated with increased systemic inflammation (Krabbe et al., 2004; Muntner et al., 2004) . Although the present study clearly suffers from the limitations common to all cross-sectional investigations, a number of specific weaknesses should also be addressed. First, the present study employed a commercially available immunoassay directed against free IGF-I. Thus, as some studies have indicated the possibility of competitive binding of the detection antibody with IGF-I bound to low-molecular-weight IGFBP-3 fragments (Rabkin et al., 1996) , we cannot exclude the possibility that we have overestimated circulating levels of free IGF-I. However, our detected levels for IGF-I show similar magnitude and spread as those of comparable studies in ESRD patients (Rabkin et al., 1996; Frystyk et al., 1999; Powell et al., 1999) , although any errors in IGF-I levels are likely to be systematic and thus have little impact on the reported findings. Secondly, without one accepted golden standard by which to evaluate malnutrition and wasting in ESRD, the present study must by necessity make use of a number of different methods to adequately illustrate the clinical status of the examined patients. It is therefore not surprising that some conflicting results are reported in this and other studies. Finally, we did not measure GH, an important determinant of IGF-I activity in healthy individuals (Hardouin et al., 1989) . Given the circadian rhythm of GH secretion (Veldhuis et al., 1991) and the alterations of its binding proteins and receptors in uremia (Martinez et al., 1999) , GH levels are not easily interpreted in ESRD. Indeed, other studies in ESRD have been unable to show any correlation between single measurements of GH levels and either IGF-I, IGFBP-1 or IGFBP-3 (Hokken- Koelega et al., 1990; Iglesias et al., 2004) .
In conclusion, the present study demonstrates that both IGF-I and IGFBP-1 appear to correlate well with markers of protein-energy malnutrition and sarcopenia in ESRD. However, IGF-I is also influenced by age, whereas IGFBP-1 is influenced by glucose metabolism. IGF-I levels also covariate with both IGFBP-1 (negatively) and IGFBP-3 (positively). IGFBP-3 is not a good marker of nutrition in ESRD, but is related to inflammatory parameters and may thus impact the bioactivity of IGF-I, with increased inflammation leading to decreased levels of IGFBP-3 and consequently to increased levels of free IGF-I.
